USD10
GILD Ações
Conheça: Gilead SciencesGilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
USD10
GILD Ações
Conheça: Gilead SciencesGilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Estatísticas
JANELA DE NEGOCIAÇÃO
Fechado
ABRE ÀS
23 de mar. at 13:30 GMT+0
CAPITALIZAÇÃO DE MERCADO
US$ 171,20 bi
PREÇO DE ABERTURA
Não há dados suficientes
MÍNIMA (1 ano)
US$ 93,37
MÁXIMA (1 ano)
US$ 157,29
MÍNIMA (24 horas)
US$ 136,52
MÁXIMA (24 horas)
US$ 137,74
VOLUME (24 horas)
US$ 865,00